Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
Year: 2016
Type: article
Abstract: Background: Endothelial dysfunction caused by increased oxidative stress is a critical initiator of macro- and micro-vascular disease development in diabetic patients. Ipragliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. The aim of the present study was to examine whether ipragliflozin attenuates endothelial dysfunction in diabetic mice. Methods: Eight-week-old male C57BL/6 mice were treated with streptozotocin (150 mg/kg) by a single intraperitoneal injection to induce diabetes mellitus. At three days of injection, ipragliflozin (3 mg/kg/day) was administered via gavage for 3 weeks. Vascular function was assessed by isometric tension recording. Human umbilical endothelial cells (HUVEC) were used for in vitro experiments. RNA and protein expression were examined by quantitative RT-PCR (qPCR) and western blot, respectively. Oxidative stress was determined by measuring urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) level. Results: Ipragliflozin administration significantly reduced blood glucose level (P<0.01) and attenuated the impairment of endothelial function in diabetic mice, as determined by acetylcholine-dependent vasodilation (P<0.001). Ipragliflozin did not alter metabolic parameters such as body weight and food intake. Ipragliflozin administration ameliorated impaired phosphorylation of Akt and eNOSSer1177 in the abdominal aorta and reduced reactive oxygen species generation as determined by urinary excretion of 8-OHdG in diabetic mice. Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules (e.g.; MCP-1, VCAM-1 and ICAM-1) in the abdominal aorta (P<0.05, respectively). In in vitro studies, incubation with methylglyoxal, one of the advanced glycation end products, significantly impaired phosphorylation of Akt and eNOSSer1177 (P<0.01, respectively) and increased the expression of MCP-1, VCAM-1, and ICAM-1 in HUVEC. Conclusion: Ipragliflozin improved hyperglycemia and prevented the development of endothelial dysfunction under a hyperglycemic state, at least partially by attenuation of oxidative stress.
Institution: Tokushima University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: SGLT2 inhibitors, endothelial dysfunction, diabetic vascular disease, streptozotocin-induced diabetes, oxidative stress, advanced glycation end products, methylglyoxal, Akt phosphorylation, MCP-1, VCAM-1, ICAM-1, 8-hydroxy-2'-deoxyguanosine, human umbilical vein endothelial cells, glycemic control
Open Access status: gold
Estimated APC paid: $3,801
Awards: Elucidation of molecular mechanism of plaque destabilization and identification of predictable factors for acute coronary syndrome, G3266383777, A study to elucidate the mechanism by which sterile chronic inflammation occurs in arterial wall and perivascular adipose tissue, The role of TLR9 in the development of insulin resistance, Development of a novel revascularization method to treat diffuse coronary artery diseases with transplantation of artery and adipose tissues, Elucidation of concept of ectopic fat consortium of cardiac fat, ectopic fat and sarcopenia and life-style diseases, Development of therapies for severe ischemic cardiomyopathy to substute heart transplantation, G6192415659, G6351372631, Visualization of chronic inflammation in arterial wall and perivascular adipose tissue
OpenAlex ID: W2535658655
